Induction Therapy for Pediatric Focal Proliferative Lupus Nephritis: Cyclophosphamide Versus Mycophenolate Mofetil

Keith K. Lau, Bettina H. Ault, Deborah P. Jones, Lavjay Butani

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Purpose of the study: Although cyclophosphamide has been used with success in children, mycophenolate may be a better alternative with less toxicity. The objective of this study is to determine the efficacy of mycophenolate compared with cyclophosphamide as induction therapy in children with class III lupus nephritis. Methods: We retrospectively studied pediatric patients with class III lupus nephritis from two pediatric centers from January 1991 to December 2005 who were treated either with monthly cyclophosphamide or mycophenolate mofetil for the first 6 months. Thirteen patients were studied, with seven patients in the cyclophosphamide group and six patients in the mycophenolate group. Results: At 6 months, in the cyclophosphamide group, no patient had achieved complete remission, while 57% were in partial remission. In the mycophenolate group, 66% had achieved complete remission, 17% were in partial remission, and 17% were not in remission. Discussion: In a small group of children with class III lupus nephritis, we observed a trend of more patients in the mycophenolate group achieving remission at 6 months. However, the long-term benefit of using mycophenolate as an induction agent is still unclear.

Original languageEnglish (US)
Pages (from-to)282-288
Number of pages7
JournalJournal of Pediatric Health Care
Volume22
Issue number5
DOIs
StatePublished - Sep 2008

Fingerprint

Mycophenolic Acid
Lupus Nephritis
Cyclophosphamide
Pediatrics
Therapeutics

Keywords

  • cyclophosphamide
  • induction
  • Lupus nephritis
  • mycophenolate mofetil
  • outcomes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Induction Therapy for Pediatric Focal Proliferative Lupus Nephritis : Cyclophosphamide Versus Mycophenolate Mofetil. / Lau, Keith K.; Ault, Bettina H.; Jones, Deborah P.; Butani, Lavjay.

In: Journal of Pediatric Health Care, Vol. 22, No. 5, 09.2008, p. 282-288.

Research output: Contribution to journalArticle

@article{4533252a8e874b6792468a3863cce339,
title = "Induction Therapy for Pediatric Focal Proliferative Lupus Nephritis: Cyclophosphamide Versus Mycophenolate Mofetil",
abstract = "Purpose of the study: Although cyclophosphamide has been used with success in children, mycophenolate may be a better alternative with less toxicity. The objective of this study is to determine the efficacy of mycophenolate compared with cyclophosphamide as induction therapy in children with class III lupus nephritis. Methods: We retrospectively studied pediatric patients with class III lupus nephritis from two pediatric centers from January 1991 to December 2005 who were treated either with monthly cyclophosphamide or mycophenolate mofetil for the first 6 months. Thirteen patients were studied, with seven patients in the cyclophosphamide group and six patients in the mycophenolate group. Results: At 6 months, in the cyclophosphamide group, no patient had achieved complete remission, while 57{\%} were in partial remission. In the mycophenolate group, 66{\%} had achieved complete remission, 17{\%} were in partial remission, and 17{\%} were not in remission. Discussion: In a small group of children with class III lupus nephritis, we observed a trend of more patients in the mycophenolate group achieving remission at 6 months. However, the long-term benefit of using mycophenolate as an induction agent is still unclear.",
keywords = "cyclophosphamide, induction, Lupus nephritis, mycophenolate mofetil, outcomes",
author = "Lau, {Keith K.} and Ault, {Bettina H.} and Jones, {Deborah P.} and Lavjay Butani",
year = "2008",
month = "9",
doi = "10.1016/j.pedhc.2007.07.006",
language = "English (US)",
volume = "22",
pages = "282--288",
journal = "Journal of Pediatric Health Care",
issn = "0891-5245",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Induction Therapy for Pediatric Focal Proliferative Lupus Nephritis

T2 - Cyclophosphamide Versus Mycophenolate Mofetil

AU - Lau, Keith K.

AU - Ault, Bettina H.

AU - Jones, Deborah P.

AU - Butani, Lavjay

PY - 2008/9

Y1 - 2008/9

N2 - Purpose of the study: Although cyclophosphamide has been used with success in children, mycophenolate may be a better alternative with less toxicity. The objective of this study is to determine the efficacy of mycophenolate compared with cyclophosphamide as induction therapy in children with class III lupus nephritis. Methods: We retrospectively studied pediatric patients with class III lupus nephritis from two pediatric centers from January 1991 to December 2005 who were treated either with monthly cyclophosphamide or mycophenolate mofetil for the first 6 months. Thirteen patients were studied, with seven patients in the cyclophosphamide group and six patients in the mycophenolate group. Results: At 6 months, in the cyclophosphamide group, no patient had achieved complete remission, while 57% were in partial remission. In the mycophenolate group, 66% had achieved complete remission, 17% were in partial remission, and 17% were not in remission. Discussion: In a small group of children with class III lupus nephritis, we observed a trend of more patients in the mycophenolate group achieving remission at 6 months. However, the long-term benefit of using mycophenolate as an induction agent is still unclear.

AB - Purpose of the study: Although cyclophosphamide has been used with success in children, mycophenolate may be a better alternative with less toxicity. The objective of this study is to determine the efficacy of mycophenolate compared with cyclophosphamide as induction therapy in children with class III lupus nephritis. Methods: We retrospectively studied pediatric patients with class III lupus nephritis from two pediatric centers from January 1991 to December 2005 who were treated either with monthly cyclophosphamide or mycophenolate mofetil for the first 6 months. Thirteen patients were studied, with seven patients in the cyclophosphamide group and six patients in the mycophenolate group. Results: At 6 months, in the cyclophosphamide group, no patient had achieved complete remission, while 57% were in partial remission. In the mycophenolate group, 66% had achieved complete remission, 17% were in partial remission, and 17% were not in remission. Discussion: In a small group of children with class III lupus nephritis, we observed a trend of more patients in the mycophenolate group achieving remission at 6 months. However, the long-term benefit of using mycophenolate as an induction agent is still unclear.

KW - cyclophosphamide

KW - induction

KW - Lupus nephritis

KW - mycophenolate mofetil

KW - outcomes

UR - http://www.scopus.com/inward/record.url?scp=50249187148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50249187148&partnerID=8YFLogxK

U2 - 10.1016/j.pedhc.2007.07.006

DO - 10.1016/j.pedhc.2007.07.006

M3 - Article

C2 - 18761229

AN - SCOPUS:50249187148

VL - 22

SP - 282

EP - 288

JO - Journal of Pediatric Health Care

JF - Journal of Pediatric Health Care

SN - 0891-5245

IS - 5

ER -